ATIII-independence of anticoagulant effect of human urinary soluble thrombomodulin

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 8, 1999, Pages 503-511

  Imada, K ^a   Takahashi, Y ^a   Hosaka, Y ^a   Adachi, T ^a   Niina, H ^a   Mochizuki, H ^a  

^a MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

Antithrombin III; Disseminated intravascular coagulation; F(ab')2 fragment; Heparins; Human urinary soluble thrombomodulin

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; HEPARIN; THROMBOMODULIN; THROMBOPLASTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG MECHANISM; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT;

EID: 0033382008     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199912000-00008     Document Type: Article

References (35)

1. Rosenberg RD, Damus PS. The purification and mechanism of action of antithrombin heparin cofactor. J Biol Chem 1973; 248: 6490-6505.
2. Buchanan MR, Boneu B, Ofosu F, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201.
3. Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981; 10: 369-390.
4. Bick RL. Clinical relevance of antithrombin III. Semin Thromb Hemost 1982; 8: 276-287.
5. Schulman S, Tengborn L. Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III. Thromb Haemost 1992; 68: 634-636.
6. Hull RD, Pineo GF. Therapeutic use of low-molecular weight heparins. Haemostasis 1993; 23 (Suppl 1): 2-9.
7. Harenberg J, Kallenbach B, Martin U, Dempfle CE, Zimmermann R, Kübler W, et al. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res 1990; 59: 639-650.
8. Frampton JE, Faulds D. Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. Drugs 1994; 47: 652-676.
9. Salzman EW. Heparin for prophylaxis of venous thromboembolism. Ann NY Acad Sci 1989; 556: 371-377.
10. Mätzsch T, Bergqvist D, Fredin H, Hedner U, Østergaard P. Influence of a low molecular weight heparin on the inhibition of factor Xa and thrombin in hip surgery. Thromb Res 1989; 56: 559-564.
11. Langley PG, Keays R, Hughes RD, Forbes A, Delvos U, Williams R. Antithrombin III supplementation reduces heparin requirement and platelet loss during hemodialysis of patients with fulminant hepatic failure. Hepatology 1991; 14: 251-256.
12. Schachinger V, Allert M, Kasper W, Just H, Vach W, Zeiher AM. Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty. Results of a prospective, randomized trial. Circulation 1994; 90: 2258-2266.
13. Grip L, Blomback M, Egberg N, Olsson A, Svane B, Velander M. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study. Eur Heart J 1997; 18: 443-449.
14. Despotis GJ, Levine V, Joist JH, Joiner-Maier D, Spintznagel E. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg 1997; 85: 498-506.
15. Cosmi B, Agnelli G, Young E, Hirsh J, Weitz J. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate. Thromb Haemost 1993; 70: 443-447.
16. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
17. Kumada T, Abiko Y. Comparative study on heparin and a synthetic thrombin inhibitor No. 805 (MD-805) in experimental antithrombin III-deficient animals. Thromb Res 1981; 24: 285-298.
18. Aoki Y, Ohishi R, Takei R, Matsuzaki O, Mohri M, Saitoh K, et al. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III. Thromb Haemost 1994; 71: 452-455.
19. Takahashi Y, Hosaka Y, Niina H, Nagasawa K, Naotsuka M, Sakai, K, et al. Soluble thrombomodulin purified from human urine exhibits a potent anticoagulant effect in vitro and in vivo. Thromb Haemost 1995; 73: 805-811.
20. Takahashi Y, Hosaka Y, Imada K, Adachi T, Niina H, Watanabe M, et al. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin. Thromb Haemost 1997; 77: 789-795.
21. De Reys S, Blom C, Lepoudre B, Declerck PJ, De Ley M, Vermylen J, et al. Human platelet aggregation by murine monoclonal antiplatelet antibodies is subtype-dependent. Blood 1993; 81: 1792-1800.
22. FAK phosphorylation in platelets. J Biol Chem 1996; 271: 16332-16337.
23. Sylvestre D, Clynes R, Ma N, Warren H, Carroll MC, Ravetch JV. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J Exp Med 1996; 184: 2385-2392.
24. Koide T. Isolation and characterization of antithrombin III from human, porcine and rabbit plasma, and rat serum. J Biochem 1979; 86: 1841-1850.
25. 2 fragments from mouse IgG of various subclasses. J Immunol Methods 1983; 56: 235-243.
26. Easterbrook-Smith SB, Vandenberg RJ, Alden JR. The role of Fc: Fc interactions in insoluble immune complex formation and complement activation. Mol Immunol 1988; 25: 1331-1337.
27. Kilchherr E, Schumaker VN, Phillips ML, Curtiss LK. Activation of the first component of human complement, C1, by monoclonal antibodies directed against different domains of subcomponent C1q. J Immunol 1986; 137: 255-262.
28. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263: 18205-18212.
29. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990; 265: 3809-8814.
30. Takahashi Y, Hosaka Y, Imada K, Adachi T, Niina H, Mochizuki H. Species specificity of the anticoagulant activity of human urinary soluble thrombomodulin. Thromb Res 1998; 89: 187-197.
31. Thompson EA, Salem HH. The effects of human thrombomodulin on the inactivation of thrombin by its serum inhibitors. Thromb Haemost 1987; 58:806-810.
32. Hirahara K, Koyama M, Matsuishi T, Kurata M. The effect of human thrombomodulin on the inactivation of thrombin by human antithrombin III. Thromb Res 1990; 57: 117-126.
33. Bayston TA, Lane DA. Antithrombin: molecular basis of deficiency. Thromb Haemost 1997; 78: 339-343.
34. Castelino DJ, Salem HH. Natural anticoagulants and the liver. J Gastroenterol Hepatol 1997; 12: 77-83.
35. Rubin RN, Colman RW. Disseminated intravascular coagulation. Approach to treatment. Drugs 1992; 44: 963-971.